アトピー性皮膚炎：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.2 Symptoms 29
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 31
4.2.1 Children ages ≤10 years are three times more likely to develop atopic dermatitis 32
4.2.2 Family history of atopic disease increases the risk of atopic dermatitis six-fold 33
4.2.3 Allergens are associated with a six-fold risk of atopic dermatitis 34
4.2.4 Breastfeeding for more than four months protects children from atopic dermatitis 35
4.2.5 Asthma, allergic rhinitis and allergic conjunctivitis commonly occur with atopic dermatitis 36
4.2.6 Atopic dermatitis patients are up to three times more likely to have psychiatric disorders 37
4.3 Global Trends 38
4.3.1 US 39
4.3.2 5EU 39
4.3.3 Japan 43
4.3.4 China 43
4.3.5 India 44
4.4 Forecast Methodology 45
4.4.1 Sources Used 48
4.4.2 Sources Not Used 55
4.5 Forecast Assumptions and Methods 56
4.5.1 US 56
4.5.2 France 57
4.5.3 Germany 57
4.5.4 Italy 58
4.5.5 Spain 59
4.5.6 UK 59
4.5.7 Japan 60
4.5.8 China 61
4.5.9 India 61
4.6 Epidemiology Forecast of Atopic Dermatitis (2012-2022) 62
4.6.1 Lifetime Prevalent Cases of Atopic Dermatitis 62
4.6.2 Age-Specific Prevalent Cases of Lifetime Atopic Dermatitis 64
4.6.3 Sex-Specific Prevalent Cases of Lifetime Atopic Dermatitis 67
4.6.4 Age-Standardized Lifetime Prevalence of Atopic Dermatitis 68
4.6.5 Prevalent Cases of Atopic Dermatitis by Severity 69
4.7 Discussion 71
4.7.1 Conclusions on Epidemiological Trends 71
4.7.2 Limitations of the Analysis 73
4.7.3 Strengths of the Analysis 74
5 Disease Management 75
5.1 Diagnosis 75
5.2 Treatment Overview 77
5.3 US 82
5.3.1 Diagnosis 82
5.3.2 Clinical Practice 85
5.4 France 87
5.4.1 Diagnosis 87
5.4.2 Clinical Practice 89
5.5 Germany 91
5.5.1 Diagnosis 91
5.5.2 Clinical Practice 93
5.6 Italy 95
5.6.1 Diagnosis 95
5.6.2 Clinical Practice 96
5.7 Spain 97
5.7.1 Diagnosis 97
5.7.2 Clinical Practice 99
5.8 UK 100
5.8.1 Diagnosis 100
5.8.2 Clinical Practice 102
5.9 Japan 104
5.9.1 Diagnosis 104
5.9.2 Clinical Practice 106
5.10 China 107
5.10.1 Diagnosis 107
5.10.2 Clinical Practice 108
5.11 India 109
5.11.1 Diagnosis 109
5.11.2 Clinical Practice 110
6 Competitive Assessment 112
6.1 Overview 112
6.2 Strategic Competitor Assessment 113
6.3 Product Profiles – Major Brands 114
6.3.1 Protopic (tacrolimus) 114
6.3.2 Elidel 122
6.3.3 Cyclosporine (numerous generic names) 129
6.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 133
6.4 Product Profiles – Off-Label Therapies 135
6.4.1 Xolair (omalizumab) 135
6.4.2 Actimmune (interferon gamma-1b) 140
7 Opportunity and Unmet Need 146
7.1 Overview 146
7.2 Unmet Needs 147
7.2.1 A Systemic Drug for Severe Recalcitrant Patients 147
7.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 148
7.2.3 A Drug that Effectively Controls Patients’ Pruritus 149
7.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 151
7.2.5 A Drug that Induces Disease Remission 152
7.2.6 Improved Quality of Life for Both Patients and their Carers 152
7.3 Unmet Needs Gap Analysis 153
7.4 Opportunities 154
7.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 154
7.4.2 Predictive Tests for Patient Stratification 154
7.4.3 More Therapeutic Options that Address Patients’ Pruritus 155
8 Pipeline Assessment 156
8.1 Overview 156
8.2 Clinical Trial Mapping 157
8.2.1 Clinical Trials by Country 157
8.3 Clinical Trials by Phase and Trial Status 158
8.4 Promising Drugs in Clinical Development 159
8.4.1 Dupilumab (SAR231893/ REGN668) 161
8.4.2 AN2728 172
8.4.3 Phase II Pipeline Products 182
9 Current and Future Players 184
9.1 Overview 184
9.2 Trends in Corporate Strategy 186
9.3 Company Profiles 188
9.3.1 Astellas 188
9.3.2 Meda 191
9.3.3 Regeneron 193
9.3.4 Anacor 195
10 Market Outlook 198
10.1 Global Markets 198
10.1.1 Forecast 198
10.1.2 Global Drivers and Barriers 202
10.2 US 207
10.2.1 Forecast 207
10.2.2 Key Events 210
10.2.3 Drivers and Barriers 211
10.3 France 213
10.3.1 Forecast 213
10.3.2 Key Events 216
10.3.3 Drivers and Barriers 217
10.4 Germany 219
10.4.1 Forecast 219
10.4.2 Key Events 222
10.4.3 Drivers and Barriers 223
10.5 Italy 225
10.5.1 Forecast 225
10.5.2 Key Events 228
10.5.3 Drivers and Barriers 229
10.6 Spain 231
10.6.1 Forecast 231
10.6.2 Key Events 233
10.6.3 Drivers and Barriers 234
10.7 UK 235
10.7.1 Forecast 235
10.7.2 Key Events 238
10.7.3 Drivers and Barriers 239
10.8 Japan 242
10.8.1 Forecast 242
10.8.2 Key Events 244
10.8.3 Drivers and Barriers 245
10.9 China 248
10.9.1 Forecast 248
10.9.2 Key Events 250
10.9.3 Drivers and Barriers 251
10.10 India 252
10.10.1 Forecast 252
10.10.2 Key Events 254
10.10.3 Drivers and Barriers 255
11 Appendix 257
11.1 Bibliography 257
11.2 Abbreviations 273
11.3 Methodology 275
11.4 Forecasting Methodology 275
11.4.1 Diagnosed Atopic Dermatitis Patients 275
11.4.2 Percent Drug-treated Patients 276
11.4.3 Drugs Included in Each Therapeutic Class 276
11.4.4 Launch and Patent Expiry Dates 276
11.4.5 General Pricing Assumptions 277
11.4.6 Individual Drug Assumptions 278
11.4.7 Generic Erosion 280
11.4.8 Pricing of Pipeline Agents 281
11.5 Physicians and Specialists Included in this Study 282
11.6 Primary Research – Prescriber Survey 283
11.7 About the Authors 284
11.7.1 Author 284
11.7.2 Epidemiologist 285
11.7.3 Global Head of Healthcare 285
11.8 About GlobalData 286
11.9 Disclaimer 286